Transgenic Mouse Facility

$213,095P30FY2025CANIH

University Of Chicago, Chicago IL

Investigators

Linked publications, trials & patents

Paper 39661064 Paper 39579248 Paper 39438113 Paper 39374047 Paper 39270007 Paper 39141403 Paper 39114540 Paper 39108474 Paper 39071306 Paper 39069988 Paper 38883758 Paper 38881356 Paper 38849889 Paper 38810242 Paper 38771643 Paper 38752924 Paper 38735044 Paper 38716867 Paper 38691450 Paper 38632339 Paper 38561491 Paper 38548994 Paper 38536082 Paper 38533736 Paper 38496521 Paper 38427437 Paper 38421866 Paper 38381713 Paper 38294692 Paper 38294689 Paper 38293065 Paper 38219706 Paper 38213818 Paper 38190286 Paper 38186960 Paper 38175791 Paper 38155245 Trial NCT02573363 Trial NCT02573220 Trial NCT02542202 Trial NCT02540876 Trial NCT02485535 Trial NCT02420210 Trial NCT02399371 Trial NCT02389517 Trial NCT02366819 Trial NCT02333188 Trial NCT02333162 Trial NCT02275533 Trial NCT02258659 Trial NCT02213913 Trial NCT02199665 Trial NCT02122172 Trial NCT02046421 Trial NCT02012296 Trial NCT01949740 Trial NCT01861301 Trial NCT01696955 Trial NCT01576172 Trial NCT01307618 Trial NCT01281176 Trial NCT01278615 Trial NCT01267266 Trial NCT01256385 Trial NCT01208051 Trial NCT01174264 Trial NCT01122888 Trial NCT01076543 Trial NCT01064622 Trial NCT00859937 Trial NCT00720174 Trial NCT00504153 Trial NCT00436579 Trial NCT00387335 Trial NCT00381641 Trial NCT00376688 Trial NCT00369551 Trial NCT00351975 Trial NCT00303862 Trial NCT00290472 Trial NCT00265798 Trial NCT00126542 Trial NCT00095784 Trial NCT00091026 Trial NCT00087373 Trial NCT00062075 Trial NCT00058019 Trial NCT00055913 Trial NCT00039416 Trial NCT00027703 Trial NCT00023946 Patent 7192711 Patent 6870037 Patent 6482934 Patent 6387619 Patent 6043216 Patent 5916752 Patent 5786344 Patent 5698686 Patent 5618917

Abstract

PROJECT SUMMARY/ABSTRACT - TRANSGENIC MOUSE FACILITY (TMF) The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) Transgenic Mouse Facility (TMF) supports the development of state-of-the-art mouse models of cancer for University of Chicago Medicine Comprehensive Cancer Center (UCCCC) investigators. The TMFâs major objective is to provide high quality, cost-effective, custom services related to genetically engineered mouse models (GEMMs) tailored to the needs of individual researcher. TMF supports the scientific needs of UCCCC investigators related to the generation, breeding and maintenance of genetically engineered mice. In the reporting period, 19 unique UCCCC members (63% MMC, 37% IC) utilized TMF for their research. In addition, 31 cancer- related federal grants, and 30 cancer relevant peer reviewed publications (37% in journals with impact factor > 10) resulted from research involving the TMF. The TMF allows investigators to maintain intellectual ownership of the models generated, an advantage over commercial services. Future efforts are aimed at maintaining the high-quality services offered. TMF anticipates increasing usage through increasing demand for animals with patient specific mutations in the next CCSG cycle. To meet the demand, TMF will continue to evaluate rapidly evolving gene editing technologies for efficiency and application to animal model development and ensure that staff are trained in new approaches both on-site and through participating in external workshops.

View original record on NIH RePORTER →